Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
Read More
Tag: Diabetic macular edema
Roche’s faricimab hits the mark in diabetic macular edema study
Treatment demonstrated non-inferior visual acuity gains compared to Regeneron’s Eylea
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
